Free Practice Questions for Egyptian Board Clinical Oncology

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card

100+ Questions

100% Free

Loading practice questions...

Same family resources

Explore More Egyptian Board Specialty Certifications (البورد المصري)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Exam Review

Key Facts: Egyptian Board Clinical Oncology Exam

Law 12/2022

Governing Legislation (EHC)

Egyptian Health Council

3 Parts

Examination Stages (Part 1, 2 & Clinical OSCE)

EHC Regulations

Angoff / Hofstee

Written Standard Setting Method

EHC Assessment Framework

100 MCQs

Practice Bank Study Items

OpenExamPrep

The Egyptian Board in Clinical Oncology is governed by the Egyptian Health Council under Law 12/2022 and Decree 3798/2023. It consists of Part 1 (cancer biology, radiation physics/radiobiology, pharmacology, statistics; held March/August), Part 2 (clinical solid tumors, systemic regimens, radiotherapy indications, oncologic emergencies, palliative care; held April/September), and Part 3 (clinical OSCE, contouring, case management; held Dec/Jan). This 100-question MCQ bank is an English-language study aid for Part 1 and Part 2 tumor staging, regimen selection, and treatment sequencing; it is not a clinical OSCE simulation.

Sample Egyptian Board Clinical Oncology Practice Questions

Try these sample questions to review concepts for the Egyptian Board Clinical Oncology exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 48-year-old patient with an Li-Fraumeni syndrome family history undergoes genomic sequencing revealing a germline TP53 missense mutation. Which cellular event is predominantly impaired following exposure of these cells to ionizing radiation?

A.Transcriptional transactivation of CDKN1A (p21) mediating G1/S cell cycle checkpoint arrest

B.Dephosphorylation of the retinoblastoma protein by protein phosphatase 1

C.Direct endonucleolytic cleavage of homologous DNA strands during meiotic recombination

D.Recruitment of DNA polymerase beta during base excision repair of single-strand breaks

Explanation: Wild-type p53 acts as a critical transcription factor in response to DNA double-strand breaks caused by ionizing radiation. Stabilized p53 transactivates CDKN1A, which encodes the p21 WAF1/CIP1 cyclin-dependent kinase inhibitor, arresting cells at the G1/S checkpoint to permit DNA repair or initiate apoptosis. Loss-of-function TP53 mutations abrogate this G1 arrest.

2In the classical mammalian cell cycle control pathway, which molecular mechanism directly enables the transition of a cell across the restriction point from late G1 into S phase?

A.Proteasomal degradation of cyclin E triggered by unphosphorylated Rb protein binding

B.Hyperphosphorylation of the retinoblastoma protein (pRb) leading to the release of free E2F transcription factors

C.Ubiquitination and destruction of the anaphase-promoting complex by securin

D.Nuclear export and cytosolic sequestration of cyclin-dependent kinase 2

Explanation: In early G1 phase, unphosphorylated or hypophosphorylated pRb binds to E2F transcription factors, repressing E2F-responsive genes. Phosphorylation of pRb by CDK4/6-cyclin D and subsequently by CDK2-cyclin E complexes causes pRb hyperphosphorylation, releasing E2F to drive transcription of genes required for DNA replication and S-phase entry.

3A postmenopausal woman with ER-positive, HER2-negative metastatic breast cancer is initiated on palbociclib plus letrozole. What is the precise pharmacological mechanism of action of palbociclib in controlling tumor growth?

A.Direct degradation of the estrogen receptor alpha through proteasomal polyubiquitination

B.Allosteric inhibition of the PI3K catalytic subunit alpha preventing AKT phosphorylation

C.Selective catalytic inhibition of CDK4 and CDK6 preventing pRb phosphorylation and inducing G1 arrest

D.Covalent binding to the tubulin beta-subunit preventing mitotic spindle assembly

Explanation: Palbociclib is an orally active, highly selective small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By blocking CDK4/6 catalytic activity in complex with cyclin D, it prevents the phosphorylation of the retinoblastoma protein, maintaining pRb in its active tumor-suppressive state and inducing robust G1 cell cycle arrest.

4During the multi-step progression of solid neoplasms, tumors undergo an 'angiogenic switch' to sustain expansion beyond microscopic dimensions. Which molecular event directly orchestrates this capability under intratumoral hypoxic conditions?

A.Hydroxylation of HIF-1alpha by prolyl hydroxylase domain enzymes promoting VHL binding

B.Epigenetic silencing of the thrombospondin-1 promoter via promoter hypermethylation alone

C.Cleavage of membrane-bound VEGFR2 by matrix metalloproteinase-9 into inactive fragments

D.Stabilization of HIF-1alpha leading to nuclear translocation and transcriptional upregulation of VEGF-A

Explanation: Under normoxic conditions, HIF-1alpha is hydroxylated by prolyl hydroxylases and targeted for proteasomal destruction by the von Hippel-Lindau (VHL) E3 ubiquitin ligase. Under hypoxia, prolyl hydroxylases lack oxygen cofactor activity; HIF-1alpha accumulates, dimerizes with HIF-1beta, translocates to the nucleus, and transactivates genes containing hypoxia-response elements, prominently VEGF-A.

5A pathology specimen from an IDH-wildtype glioblastoma demonstrates activating mutations in the promoter region of the TERT gene (C228T/C250T). How do these mutations confer replicative immortality to neoplastic cells?

A.Creating de novo consensus binding motifs for ETS/GABP transcription factors that augment telomerase reverse transcriptase expression

B.Accelerating the rate of telomeric attrition during each cycle of lagging-strand DNA synthesis

C.Disassembling the shelterin complex to trigger non-homologous end joining of chromosomal termini

D.Inducing alternative lengthening of telomeres (ALT) through homologous sister-chromatid exchange

Explanation: The canonical TERT promoter core mutations (C228T and C250T) generate identical 11-base-pair de novo binding motifs (CCGGAA) for ETS-family transcription factors, particularly GABP. This leads to marked transcriptional upregulation of the catalytic subunit of telomerase (hTERT), maintaining telomere length and enabling indefinite cellular replication.

6Which of the following biological comparisons accurately distinguishes Homologous Recombination (HR) from Non-Homologous End Joining (NHEJ) in repairing radiation-induced DNA double-strand breaks?

A.NHEJ requires extensive 5'-to-3' end resection orchestrated by the MRN complex and CtIP

B.HR is high-fidelity and restricted to late S and G2 phases, whereas NHEJ operates throughout all cell cycle phases

C.HR utilizes DNA-PKcs, Ku70, and Ku80 to tether free ends without need for a template sequence

D.NHEJ is entirely error-free and predominates during the G1 phase of quiescent cancer stem cells

Explanation: Homologous recombination (HR) is an error-free repair pathway that requires an undamaged sister chromatid as a template, restricting its activity to the late S and G2 phases of the cell cycle. In contrast, non-homologous end joining (NHEJ) directly ligates broken DNA ends without requiring a homologous template, functions across all cell cycle phases (predominating in G0/G1), and is intrinsically error-prone.

7A patient harboring a deleterious germline BRCA2 mutation develops high-grade serous ovarian carcinoma and receives maintenance therapy with olaparib. What is the molecular basis of synthetic lethality observed with this therapeutic strategy?

A.Inhibition of topoisomerase I prevents single-strand uncoiling, selectively inducing apoptosis in BRCA-intact stromal cells

B.Upregulation of RAD51 nucleofilament formation leads to toxic excessive interstrand cross-link repair

C.PARP inhibition traps PARP-DNA complexes and stalls replication forks, generating double-strand breaks that homologous recombination-deficient cells cannot repair

D.Depletion of intracellular NAD+ stores triggers catastrophic necrosis independent of the DNA damage response

Explanation: PARP1 detects and facilitates the repair of single-strand DNA breaks. PARP inhibitors like olaparib not only inhibit catalytic activity but also trap PARP1 on damaged DNA. When DNA replication forks encounter these trapped complexes, they collapse into double-strand breaks (DSBs). Normal cells repair DSBs via intact homologous recombination (HR), whereas BRCA-mutant tumor cells are HR-deficient, resulting in genomic instability and synthetic lethality.

8A patient with newly diagnosed metastatic colon cancer has immunohistochemistry demonstrating absent nuclear staining for MLH1 and PMS2 with preserved MSH2 and MSH6. What clinical and molecular phenomenon does this tumor exhibit?

A.Microsatellite stability (MSS) with hyperactive base excision repair and resistance to immune checkpoint blockade

B.Chromosomal instability (CIN) characterized by widespread aneuploidy and hyperresponsiveness to 5-FU monotherapy

C.Deficiency of nucleotide excision repair resulting in hypersensitivity to ultraviolet radiation

D.Mismatch repair deficiency (dMMR) leading to high microsatellite instability (MSI-H) and elevated neoantigen burden

Explanation: MLH1 and PMS2 form the MutL-alpha heterodimer in DNA mismatch repair (MMR). Loss of MLH1 leads to proteolytic degradation of its partner PMS2, causing MMR deficiency (dMMR) and high microsatellite instability (MSI-H). These tumors accumulate thousands of insertion-deletion mutations, generating abundant frameshift neoantigens that render them highly responsive to anti-PD-1 immune checkpoint inhibitors.

9In the sensing and transduction of radiation-induced DNA lesions, how do the phosphoinositide 3-kinase-related kinases ATM and ATR differ in their primary activation triggers and downstream signaling cascades?

A.ATM is recruited by the MRN complex to double-strand breaks and activates Chk2, whereas ATR is recruited by RPA to single-stranded DNA and activates Chk1

B.ATM senses single-stranded base oxidations via Ku70/80, whereas ATR senses intra-strand crosslinks through the Fanconi anemia core complex

C.ATM directly phosphorylates cyclin B1 to accelerate mitosis, whereas ATR halts DNA polymerase delta elongation in G1

D.ATM is restricted entirely to mitochondrial DNA damage, whereas ATR governs nuclear double-strand break repair

Explanation: ATM (ataxia-telangiectasia mutated) is primarily activated by DNA double-strand breaks; it is recruited by the MRE11-RAD50-NBS1 (MRN) complex and phosphorylates downstream targets including histone H2AX (forming gamma-H2AX) and the checkpoint kinase Chk2. In contrast, ATR (ATM- and Rad3-related) is activated by persistent single-stranded DNA coated with replication protein A (RPA), which arises at stalled replication forks, activating Chk1.

10In the linear-quadratic (LQ) model of cell survival following radiation exposure, represented by the equation S = exp(-(alpha*D + beta*D^2)), what do the parameters alpha and beta fundamentally represent?

A.Alpha denotes sublethal damage repair kinetics, while beta represents the oxygen enhancement factor

B.Alpha represents single-track, unrepairable lethal events (linear component), while beta represents lethal damage from two independent radiation tracks (quadratic component)

C.Alpha reflects late-tissue fibrosis risk, while beta denotes acute mucosal desquamation rate

D.Alpha represents the repopulation rate of tumor clonogens, while beta denotes the intrinsic cell cycle duration

Explanation: In the LQ model, the alpha parameter represents cell kill resulting from a single ionizing particle track that produces double-strand lesions (single-hit lethality, proportional to dose D). The beta parameter represents cell kill arising from two separate radiation tracks whose independently produced sublethal lesions interact to form a lethal lesion (dual-hit lethality, proportional to dose squared D^2).

About the Egyptian Board Clinical Oncology Exam

The Egyptian Board in Clinical Oncology (علاج الأورام والطب النووي) is the official national postgraduate medical qualification awarded by the Egyptian Health Council (EHC), established pursuant to Law No. 12 of 2022 and Prime Ministerial Decree No. 3798 of 2023, consolidating and replacing the legacy Egyptian Fellowship (الزمالة المصرية). The specialty curriculum delivers comprehensive training across medical oncology (cytotoxic chemotherapy, targeted small-molecule inhibitors, monoclonal antibodies, and immune checkpoint inhibitors), radiation oncology (3D conformal radiotherapy, IMRT/VMAT, stereotactic body radiation therapy, and brachytherapy), and palliative care. Important disclosure: Part Three is a dedicated practical and clinical OSCE examination incorporating radiotherapy contouring, treatment plan evaluation, and clinical case management; this 100-question multiple-choice question bank is an English-language study aid created to strengthen underlying medical knowledge, tumor staging (TNM), regimen selection, and treatment sequencing for Part One and Part Two—it is not an OSCE simulation or a substitute for hands-on clinical training.

Exam sponsor: Egyptian Health Council (EHC) — Egyptian Board (المجلس الصحي المصري — البورد المصري). The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The Egyptian Board in Clinical Oncology (علاج الأورام والطب النووي) features a three-part assessment framework governed by the Egyptian Health Council: Part One is a written MCQ examination focusing on basic cancer sciences (cancer biology & genetics, radiation physics, radiobiology, cancer pharmacology including cytotoxics, targeted therapies, and checkpoint inhibitors, and clinical trial statistics) held twice yearly in March and August. Part Two is a written MCQ examination focusing on clinical solid tumors (multidisciplinary management, TNM staging, systemic regimens, and radiation oncology across breast, lung, colorectal, prostate, head & neck, gynecologic, CNS, sarcomas, oncologic emergencies, and palliative care) held twice yearly in April and September. Part Three is an annual clinical examination (held in December/January) consisting of an Objective Structured Clinical Examination (OSCE), radiotherapy contouring and planning evaluation, and clinical case defense.

Time Limit

Varies by examination part

Passing Score

Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published

Exam / Certification Fees

Prescribed by Egyptian Health Council regulatory bylaws

Exam sponsor website

Reported exam pass rate: Determined by psychometric standard-setting per diet. Written examination cut scores (Part One and Part Two) are established using criterion-referenced standard-setting procedures (Angoff, Modified Angoff, or Hofstee). The Part Three clinical exam uses the Borderline Regression Method. There is no fixed passing percentage published. Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Official sources

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

20%

Cancer Biology, Molecular Genetics & Radiobiology

Cell cycle regulation, hallmarks of cancer, DNA damage response pathways (HRR, NHEJ, MMR), oncogene activation, linear-quadratic model, alpha/beta ratio calculations, the 4 Rs of radiobiology, and normal tissue radiation tolerance limits.

15%

Radiation Physics, Treatment Planning & Technology

Principles of medical linear accelerators, photon and electron interactions with matter, percentage depth dose, beam profiling, inverse square law, 3D conformal radiotherapy, IMRT, VMAT, stereotactic radiation (SRS/SBRT), and brachytherapy dosimetry.

20%

Antineoplastic Pharmacology & Systemic Therapeutics

Mechanisms of action, pharmacokinetics, drug interactions, and toxicities of alkylating agents, antimetabolites, topoisomerase inhibitors, microtubule poisons, platinum compounds, targeted kinase inhibitors, monoclonal antibodies, and checkpoint inhibitors.

35%

Clinical Solid Tumor Staging, Regimens & Radiotherapy

Etiology, AJCC/UICC TNM 8th edition staging, multimodal therapeutic sequencing, evidence-based systemic regimens, and radiation oncology indications across breast, thoracic, gastrointestinal, genitourinary, gynecologic, head and neck, CNS, and sarcoma malignancies.

10%

Oncologic Emergencies, Palliative Care & Trial Methodology

Management of febrile neutropenia, malignant spinal cord compression, tumor lysis syndrome, hypercalcemia of malignancy, cancer pain management, palliative radiation fractionations, and biostatistical concepts in clinical trials.

Preparing for the Egyptian Board Clinical Oncology Exam

What You Need to Know

Passing score: Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published
Assessment: The Egyptian Board in Clinical Oncology (علاج الأورام والطب النووي) features a three-part assessment framework governed by the Egyptian Health Council: Part One is a written MCQ examination focusing on basic cancer sciences (cancer biology & genetics, radiation physics, radiobiology, cancer pharmacology including cytotoxics, targeted therapies, and checkpoint inhibitors, and clinical trial statistics) held twice yearly in March and August. Part Two is a written MCQ examination focusing on clinical solid tumors (multidisciplinary management, TNM staging, systemic regimens, and radiation oncology across breast, lung, colorectal, prostate, head & neck, gynecologic, CNS, sarcomas, oncologic emergencies, and palliative care) held twice yearly in April and September. Part Three is an annual clinical examination (held in December/January) consisting of an Objective Structured Clinical Examination (OSCE), radiotherapy contouring and planning evaluation, and clinical case defense.
Time limit: Varies by examination part
Exam / certification fees: Prescribed by Egyptian Health Council regulatory bylaws Official sources

Using Our Practice Resources

Work through all 100 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

Egyptian Board Clinical Oncology: Suggested Study Strategy

1Master the linear-quadratic model: practice calculating biologically effective dose (BED) and equivalent dose in 2-Gy fractions (EQD2) across acute-responding (alpha/beta = 10) and late-responding (alpha/beta = 3) tissues.

2Review antineoplastic pharmacogenomics and dose-limiting toxicities: memorize DPYD variants for fluoropyrimidines, TPMT/NUDT15 for thiopurines, UGT1A1 for irinotecan, and anthracycline cumulative lifetime cardiotoxicity limits.

3Thoroughly memorize AJCC/UICC 8th edition TNM staging criteria and prognostic stage groups for high-yield solid tumors, especially breast, lung, colorectal, cervix, and prostate cancers.

4Understand treatment sequencing paradigms: distinguish between neoadjuvant chemoradiation vs total neoadjuvant therapy (TNT) in rectal cancer, and perioperative FLOT vs adjuvant chemoradiation in gastric cancer.

5Know immediate emergency management protocols: rapid dexamethasone dosing and imaging for suspected cord compression, hydration and rasburicase for tumor lysis syndrome, and risk-stratified antibiotic selection for febrile neutropenia.

Frequently Asked Questions

What is the governing authority of the Egyptian Board in Clinical Oncology?

The Egyptian Board (البورد المصري) is governed by the Egyptian Health Council (EHC / المجلس الصحي المصري), established under Law No. 12 of 2022 and its Executive Regulations (Prime Ministerial Decree No. 3798 of 2023). It officially replaces the legacy Egyptian Fellowship (الزمالة المصرية) and unifies postgraduate medical specialization and assessment standards across the Arab Republic of Egypt.

What is the examination structure of the Egyptian Board in Clinical Oncology?

The qualification features three distinct parts: Part One is a written MCQ exam covering applied basic cancer sciences (cancer biology, radiation physics, radiobiology, pharmacology, and trial statistics) held twice yearly in March and August. Part Two is a written MCQ exam focusing on clinical solid tumors, multimodal treatment protocols, systemic regimens, radiation therapy indications, oncologic emergencies, and palliative care held twice yearly in April and September. Part Three is an annual practical/clinical exam held in December/January comprising OSCE stations, radiotherapy planning and contouring evaluation, and clinical case discussions.

What is the passing score and standard-setting methodology for the written examinations?

There is no fixed or static percentage pass mark published by the Egyptian Health Council. The EHC utilizes criterion-referenced psychometric standard-setting methodologies—specifically the Angoff, Modified Angoff, or Hofstee methods—to establish the passing threshold for each written examination diet. The Part Three clinical exam uses the Borderline Regression Method to set station cut scores.

How many attempts are permitted for Part One?

Under Egyptian Health Council regulations, candidates are permitted a maximum of six attempts to pass the Part One written examination. Candidates must clear Part One before progressing to the advanced clinical stages of residency and sitting for Part Two.

Does this question bank substitute for Part Three clinical training?

No. Part Three of the Egyptian Board is a rigorous clinical examination comprising Objective Structured Clinical Examination (OSCE) stations, computer-based radiotherapy contouring assessments, treatment plan evaluations, and viva voce case defenses. This 100-question multiple-choice question bank is an English-language theoretical study aid designed to reinforce core knowledge, tumor staging (TNM), regimen selection, and treatment sequencing for Part One and Part Two; it is not a clinical OSCE simulation or a substitute for hands-on clinical residency training.

What official syllabus framework guides the examination?

The examination blueprint is aligned with the Egyptian Health Council reference framework and LMS training guidelines for Clinical Oncology (علاج الأورام والطب النووي), accessible via the official EHC LMS portal at https://lms.ehc.gov.eg/lms/course/index.php?categoryid=7.

Free Practice Questions for Egyptian Board Clinical Oncology

Explore More Egyptian Board Specialty Certifications (البورد المصري)

Egyptian Board — Anesthesia (Part 1 & 2)

Egyptian Board — Cardiology (Part 1 & 2)

Egyptian Board — Clinical Infectious Diseases (Part 1 & 2)

Egyptian Board — Clinical Pathology (Part 1 & 2)

Egyptian Board — Critical Care (Part 1 & 2)

Egyptian Board — Dermatology & Venereology (Part 1 & 2)